Thursday | April 24, 2025 | 3:00pm PST

Evoked Potential Tomography to Estimate Dementia Clinical Endpoints

Dementia, particularly Alzheimer’s disease (AD), remains difficult to diagnose and track due to its complex progression and lack of unified tools. The ATN framework (Amyloid, Tau, Neurodegeneration) helps structure diagnosis but is hard to apply without portable technology.

Vistim Labs’ Evoked Potential Tomography™ (EPT) offers a promising EEG-based solution that directly measures disease progression using a patented brain-mapping protocol. Unlike traditional EEG, EPT delivers precise, stimulus-driven assessments of neuron integrity. In a study of 60 patients (ranging from subjective decline to AD and Lewy Body Disease), EPT showed strong correlations (>0.75) with PET, CSF, and cognitive scores—outperforming traditional CSF-PET correlations. EPT also achieved over 90% accuracy in distinguishing patient groups and revealed new dementia subtypes. A follow-up study is underway to validate EPT's ability to predict full PET and MRI results.

Full presentation is attached in Resources.

About James Hamet

James Hamet is a serial neurotech entrepreneur and Founder/CEO of Vistim Labs, a medical device company started in 2021 to help clinicians treat dementia patients with superior diagnostic abilities.

James is an expert in his field with relevant high impact patents, publications, and business. Previously, James founded Neurable, a brain computer interface company worth $50M today, to help partially and fully paralyzed patients navigate their world. Through Neurable, James learned that these patients are most often paralyzed by neurological disorders that he believes could have been prevented with superior diagnostics. This sparked his creation of Vistim Labs—to prevent paralysis entirely. MedTech entrepreneur specialized in brain biomarkers and digital signal-processing using machine learning. Relevant publications and business experience. Co-founded Neurable, a Boston brain-computer interface company.